[Oncogenetics and molecular tumor boards in private practice: Specificities and perspectives].

doi:10.1016/j.bulcan.2026.07.004

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

[Oncogenetics and molecular tumor boards in private practice: Specificities and perspectives].

Bulletin du cancer - 1 Oct 2026

Toledano Daniel, Chibaudel Benoist, Costa Jean-Marc, Boudabous Hanene, Coude Marie-Magdelaine, Luscan Armelle, Legrand Anne, Muller Etienne, Philippe Nicolas, Corbin Aurélie Driss, Ihout Paul, Squara Pierre, Lamallem Hanah, Dinet Emile, Pujol Pascal, Toledano Alain

Abstract excerpt

BACKGROUND: Genetic counseling and molecular tumor boards have become essential components of oncology care pathways. Since 2012, a private-sector oncogenetics program supported by the National Cancer Institute (INCa), has been established within the Hauts-de-Seine health cooperation group, in connection with partner laboratories and a dedicated molecular tumor board. METHODS: The study includes...

Read the complete abstract on PubMed

Topics

Humans
Female
Private Practice
Mutation
Neoplasms
Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

France

Genetic Testing

Genetic Counseling

Breast Neoplasms

Time Factors

Neoplastic Syndromes, Hereditary

Ovarian Neoplasms

Referral and Consultation

Source

Open in PubMed

Identifiers

PMID: 42716872
DOI: 10.1016/j.bulcan.2026.07.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Oncogenetics and molecular tumor boards in private practice: Specificities and perspectives].PMID 42716872Read ↗

Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.Semantic proximity Read ↗

Clinical Integration of Germline Findings from a Tumor Testing Precision Medicine ProgramSemantic proximity Read ↗

Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort StudySemantic proximity Read ↗

Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.Semantic proximity Read ↗

Mainstream Germline Genetic Testing with Expanded Eligibility for Early Breast Cancer Patients in a Large Integrated Health System.Semantic proximity Read ↗

Optimizing the detection of hereditary predisposition in women with epithelial ovarian cancer: nationwide implementation of the Tumor-First workflow.Semantic proximity Read ↗

Germline pathogenic variants identification through Comprehensive Cancer Genome ProfilingSemantic proximity Read ↗

Opportunities to improve detection of genetic predisposition for ovarian cancer applying the Tumor-First workflow.Semantic proximity Read ↗

Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma.Semantic proximity Read ↗

Quality and Safety Imperatives in the Identification and Management of Hereditary Cancer Syndromes.Semantic proximity Read ↗

Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.Semantic proximity Read ↗

Outcomes of large panel genetic evaluation of breast cancer patients in a community-based cancer institute.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.